Vitiligo and lipohypertrophy surrounding insulin injection sites in a patient with type 1 diabetes

Abstract

We present a case of vitiligo associated with lipohypertrophy in a patient with type 1 diabetes on Lantus and Novorapid subcutaneous insulin. The patient, a 55-year-old woman, was diagnosed with type 1 diabetes 53 years ago. Following 11 years using Novorapid and Lantus she developed lipohypertrophy at her injection sites with associated depigmentation of the skin. The depigmentation has recurred following changing injection sites. We believe this is the first case of its kind to be reported in the literature and teaches a valuable lesson about the importance of examining injection sites.